Empagliflozin Disrupts a Tnfrsf12a-Mediated Feed Forward Loop That Promotes Left Ventricular Hypertrophy.
Veera Ganesh YerraSri Nagarjun BatchuGolam KabirSuzanne L AdvaniYouan LiuFerhan S SiddiqiKim A ConnellyAndrew AdvaniPublished in: Cardiovascular drugs and therapy (2021)
Empagliflozin attenuates LV enlargement in mice with hypertrophic heart failure. This effect may be mediated, at least in part, by a reduction in loading conditions which limits upregulation of the inducible, proinflammatory, and prohypertrophic TNF superfamily receptor, Tnfrsf12a. Disruption of the Tnfsf12/Tnfrsf12a feed forward system may contribute to the cardioprotective benefits of SGLT2 inhibition.
Keyphrases
- heart failure
- left ventricular
- rheumatoid arthritis
- cardiac resynchronization therapy
- cell proliferation
- acute myocardial infarction
- poor prognosis
- transcription factor
- signaling pathway
- mitral valve
- atrial fibrillation
- aortic stenosis
- type diabetes
- hypertrophic cardiomyopathy
- coronary artery disease
- transcatheter aortic valve replacement
- ejection fraction
- genome wide identification